Emcure Pharmaceuticals Ltd vs Windlas Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Emcure Pharmaceuticals Ltd is ₹ 1679 as of 30 Apr 15:30 . The P/E Ratio of Emcure Pharmaceuticals Ltd changed from 29.8 on March 2025 to 29.8 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Windlas Biotech Ltd changed from 12 on March 2022 to 35.8 on March 2025 . This represents a CAGR of 31.42% over 4 years The Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 20327 crore on March 2025 to ₹ 20327 crore on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Windlas Biotech Ltd changed from ₹ 457.9 crore on March 2022 to ₹ 2176 crore on March 2025 . This represents a CAGR of 47.65% over 4 years The revenue of Emcure Pharmaceuticals Ltd for the Dec '25 is ₹ 2365 crore as compare to the Sep '25 revenue of ₹ 2272 crore. This represent the growth of 4.06% The revenue of Windlas Biotech Ltd for the Dec '25 is ₹ 237.67 crore as compare to the Sep '25 revenue of ₹ 226.04 crore. This represent the growth of 5.15% The ebitda of Emcure Pharmaceuticals Ltd for the Dec '25 is ₹ 456.45 crore as compare to the Sep '25 ebitda of ₹ 478.6 crore. This represent the decline of -4.63% The ebitda of Windlas Biotech Ltd for the Dec '25 is ₹ 28.95 crore as compare to the Sep '25 ebitda of ₹ 32.2 crore. This represent the decline of -10.09% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 152.59 crore to ₹ 231.37 crore over 7 quarters. This represents a CAGR of 26.85% The net profit of Windlas Biotech Ltd changed from ₹ 13.48 crore to ₹ 15 crore over 7 quarters. This represents a CAGR of 6.30% The Dividend Payout of Emcure Pharmaceuticals Ltd changed from 4.3 % on March 2021 to 17.92 % on March 2025 . This represents a CAGR of 33.04% over 5 yearsThe Dividend Payout of Windlas Biotech Ltd changed from 19.79 % on March 2022 to 20.04 % on March 2025 . This represents a CAGR of 0.31% over 4 years .

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

About Windlas Biotech Ltd

Windlas Biotech Limited, formerly known as Windlas Biotech Private Limited was incorporated in 2001.
The Company got converted from a Private Limited to a Public Limited Company and the name of the Company was changed to Windlas Biotech Limited'.
A fresh Certificate of Incorporation dated April 15, 2021, granted by the Registrar of Companies, Uttarakhand at Dehradun. The Company is engaged in manufacturing and trading of pharmaceutical products.
Their manufacturing plants are located at Dehradun in Uttarakhand.
It has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports. The Company commenced operations at Dehradun Plant -IV in 2010.

FAQs for the comparison of Emcure Pharmaceuticals Ltd and Windlas Biotech Ltd

Which company has a larger market capitalization, Emcure Pharmaceuticals Ltd or Windlas Biotech Ltd?

Market cap of Emcure Pharmaceuticals Ltd is 31,850 Cr while Market cap of Windlas Biotech Ltd is 1,799 Cr

What are the key factors driving the stock performance of Emcure Pharmaceuticals Ltd and Windlas Biotech Ltd?

The stock performance of Emcure Pharmaceuticals Ltd and Windlas Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Emcure Pharmaceuticals Ltd and Windlas Biotech Ltd?

As of May 3, 2026, the Emcure Pharmaceuticals Ltd stock price is INR ₹1679.95. On the other hand, Windlas Biotech Ltd stock price is INR ₹852.7.

How do dividend payouts of Emcure Pharmaceuticals Ltd and Windlas Biotech Ltd compare?

To compare the dividend payouts of Emcure Pharmaceuticals Ltd and Windlas Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.